CervoMed

CRVO · NASDAQ

$2.29−$0.02 (−0.87%)TodayMarket closed · Oct 20, 7:43 PM ET

Prev close $2.31

Latest news

NewsOct 12, 12:13 PM ETVandana Singh
CervoMed Shows Progress in Treating Rare Aphasia Condition
Press releaseOct 12, 7:30 AM ETGlobe Newswire
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
Press releaseSep 28, 7:30 AM ETGlobe Newswire
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
Press releaseSep 10, 7:30 AM ETGlobe Newswire
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
Press releaseAug 10, 7:30 AM ETGlobe Newswire
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Press releaseAug 4, 5:15 AM ETGlobe Newswire
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
Press releaseJul 14, 7:30 AM ETGlobe Newswire
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
Press releaseJul 9, 7:30 AM ETGlobe Newswire
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
Press releaseJul 6, 7:30 AM ETGlobe Newswire
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
Press releaseJun 22, 4:05 PM ETGlobe Newswire
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Press releaseJun 18, 12:35 PM ETGlobe Newswire
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Press releaseJun 16, 3:22 PM ETGlobe Newswire
Wall Street Chases the Next Big Breakout
Press releaseJun 16, 10:18 AM ETGlobe Newswire
Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
NewsJun 16, 8:05 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Press releaseMar 5, 7:30 AM ETGlobe Newswire
CervoMed to Participate in Upcoming Investor Conferences
Press releaseNov 10, 7:00 AM ETGlobe Newswire
CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
NewsOct 8, 11:54 AM ETVandana Singh
CervoMed Drug Cut Dementia Progression Risk By 75% In Trial
NewsJul 28, 8:08 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
Press releaseMay 12, 8:00 AM ETGlobe Newswire
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
NewsApr 3, 1:06 PM ET
11 Health Care Stocks Moving In Thursday's Intraday Session
NewsApr 1, 6:28 PM ETChris Katje
EXCLUSIVE: March's 20 Most-Searched Tickers On Benzinga Pro — Where Do Tesla, Nvidia, Apple, Applovin Stock Rank?
NewsMar 27, 1:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsMar 26, 1:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsMar 24, 1:06 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsMar 21, 1:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsMar 20, 1:06 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsMar 17, 1:05 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
Press releaseMar 17, 8:00 AM ETGlobe Newswire
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
NewsMar 13, 8:09 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsMar 12, 1:07 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsDec 10, 2:00 PM ETAvi Kapoor
S&P 500 Edges Lower; AutoZone Posts Downbeat Earnings
NewsDec 10, 12:37 PM ETAvi Kapoor
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings
NewsDec 10, 10:34 AM ETPiero Cingari
US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift'
NewsDec 10, 9:49 AM ETAvi Kapoor
Dow Falls 150 Points; Oracle Posts Downbeat Results
Press releaseNov 12, 7:00 AM ETGlobe Newswire
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Press releaseAug 12, 8:00 AM ETGlobe Newswire
CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

CervoMed Shows Progress in Treating Rare Aphasia Condition

CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026

CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026

CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Wall Street Chases the Next Big Breakout

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

CervoMed to Participate in Upcoming Investor Conferences

CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

12 Health Care Stocks Moving In Monday's Pre-Market Session

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

11 Health Care Stocks Moving In Thursday's Intraday Session

EXCLUSIVE: March's 20 Most-Searched Tickers On Benzinga Pro — Where Do Tesla, Nvidia, Apple, Applovin Stock Rank?

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Monday's Intraday Session

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

S&P 500 Edges Lower; AutoZone Posts Downbeat Earnings

Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings

US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift'

Dow Falls 150 Points; Oracle Posts Downbeat Results

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates